Diabetologia JANUARY 18, 2024

Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study

Edward W. Gregg, Haiying Chen, Michael P. Bancks, Raoul Manalac, Nisa Maruthur, Medha Munshi, Rena Wing, and the Look AHEAD Research Group

Source: View publication →

Bottom Line

In a post hoc observational analysis of the Look AHEAD trial, participants achieving remission from type 2 diabetes exhibited significantly lower rates of cardiovascular disease and chronic kidney disease compared to those who did not achieve remission.

Key Findings

1. Participants who achieved any evidence of diabetes remission during follow-up experienced a 40% lower rate of composite cardiovascular disease (CVD) events (Hazard Ratio [HR], 0.60; 95% CI, 0.47–0.79).

2. Evidence of any remission was associated with a 33% lower rate of chronic kidney disease (CKD) (HR, 0.67; 95% CI, 0.52–0.87).

3. The protective association between remission and reduced disease risk was more pronounced in participants who maintained remission for longer durations.

4. Despite these long-term benefits, the prevalence of diabetes remission declined over the course of the study, with only 3% of participants remaining in remission by the 8th year.

Study Design

Design

Observational post hoc analysis

N/A

Sample

4,402

Patients

Duration

12 yr

Median

Setting

Multicenter, US

Population Overweight or obese adults with type 2 diabetes (aged 45–76) participating in the Look AHEAD study.

Intervention Achievement of diabetes remission (defined as HbA1c <6.5% and no diabetes medication usage).

Comparator Participants who did not achieve diabetes remission.

Outcome Incidence of cardiovascular disease (composite of non-fatal MI, stroke, hospitalization for angina, or CVD death) and chronic kidney disease (based on KDIGO criteria).

Study Limitations

• As an observational post hoc analysis of a randomized trial, the study cannot establish definitive causality, as unmeasured confounding variables or reverse causality may influence the association between remission and health outcomes.

• The definition of remission used—a single-point-in-time assessment of HbA1c <6.5% without diabetes medication—may not capture the stability of glycemic control as effectively as continuous monitoring or sustained remission criteria.

• The initial Look AHEAD trial was stopped early for futility regarding its primary cardiovascular outcome, suggesting that the population or intervention characteristics may limit the generalizability of these findings to broader clinical contexts.

• The study design does not account for the specific methods by which individual participants may have achieved remission (e.g., lifestyle, medication changes), which may influence the observed health benefits.

Clinical Significance

These findings suggest that achieving even temporary remission from type 2 diabetes, particularly within an intensive lifestyle framework, is associated with substantial, lasting reductions in the incidence of major microvascular and macrovascular complications like CKD and CVD, reinforcing the importance of weight management and glycemic control strategies.

Historical Context

The original Look AHEAD (Action for Health in Diabetes) trial was a landmark study launched in 2001 to determine if intensive lifestyle intervention could reduce cardiovascular events in overweight/obese individuals with type 2 diabetes. The primary trial was terminated early in 2012 due to futility regarding cardiovascular endpoints; however, ongoing analysis of the rich longitudinal data continues to provide critical insights into the long-term metabolic and clinical benefits of weight loss and diabetes remission.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the physiological definition of type 2 diabetes remission as used in the Look AHEAD study, and how does it differ from pharmacologic 'control' of blood glucose?

Key Response

In Look AHEAD, remission was defined as achieving a sub-diabetic HbA1c (<6.5%) without the use of glucose-lowering medications for at least 21 days. This represents a return to endogenous glucose homeostasis, likely through improved beta-cell function and reduced hepatic glucose production, whereas 'control' relies on exogenous agents to manage hyperglycemia without necessarily addressing the underlying metabolic pathophysiology.

Resident

The original Look AHEAD trial failed to show a primary CVD benefit for the intensive lifestyle intervention (ILI) group. How should a resident interpret the finding that the subset of patients achieving remission had significantly lower CVD rates?

Key Response

This highlights the difference between 'Intention-to-Treat' (ITT) analysis of an intervention and the biological effect of a specific outcome. While the ILI intervention was not potent enough to reduce CVD across the entire heterogeneous cohort, those who successfully achieved the metabolic state of remission derived substantial protection. This suggests that for motivated patients, the goal should be the outcome (remission) rather than just the process (lifestyle changes).

Fellow

Considering the 'legacy effect' observed in the UKPDS and DCCT trials, how does the magnitude of CVD risk reduction in Look AHEAD remitters (33–40%) compare to early intensive glycemic control using medication?

Key Response

The risk reduction in Look AHEAD remitters is comparable to or exceeds the legacy effects seen in UKPDS. This suggests that achieving drug-free remission early in the disease course provides a potent 'metabolic memory' benefit, likely by halting the accumulation of advanced glycation end-products (AGEs) and epigenetic modifications in the vasculature more effectively than pharmacologic control that leaves underlying insulin resistance unaddressed.

Attending

Look AHEAD participants with a shorter duration of diabetes and lower baseline HbA1c were more likely to achieve remission. How does this finding shift the 'window of opportunity' in your clinical teaching for newly diagnosed type 2 diabetes patients?

Key Response

It reinforces the 'remission-first' paradigm. Instead of the traditional 'step-up' approach starting with Metformin, these data support aggressive early weight loss and lifestyle intervention when the beta-cell mass is most preserved. This 'window of opportunity' allows for a potential disease-modifying effect that becomes significantly harder to achieve as the duration of diabetes and secondary complications progress.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

This post hoc analysis utilizes time-dependent Cox proportional hazards models to associate remission with outcomes. What are the inherent risks of 'healthy responder' bias in this design, and how might it confound the causal link between remission and CVD reduction?

Key Response

Healthy responder bias occurs because participants capable of achieving remission may possess unmeasured favorable characteristics (e.g., higher socioeconomic status, better baseline fitness, or specific genetic predispositions) that independently reduce CVD risk. Even with time-varying covariates, it is difficult to determine if remission itself is the causal driver of better outcomes or merely a marker for a healthier phenotype that was destined for better outcomes regardless.

Journal Editor

A critical reviewer might argue that the small percentage of remitters (approx. 12%) limits the editorial significance of this study for the general T2D population. How would you counter this argument regarding the paper's impact?

Key Response

The impact lies in proof-of-concept rather than immediate population-wide scalability. By demonstrating that remission—even when achieved by a minority—is associated with a massive reduction in CKD and CVD, the paper provides a clear evidence-based target for future therapeutic strategies (including pharmacotherapy like GLP-1RAs or bariatric surgery) that aim to induce the same physiological state of remission in a broader population.

Guideline Committee

Current ADA/EASD guidelines emphasize cardiorenal protection through SGLT2i and GLP-1RA use. Should these Look AHEAD findings prompt a revision to include 'Remission' as a co-primary treatment goal alongside 'Risk Reduction' in early-stage T2D?

Key Response

The ADA 2024 guidelines recognize remission but treat it as a secondary possibility. These findings suggest that achieving remission via lifestyle offers cardiorenal protection comparable to expensive drug classes. The committee must consider if the 'remission' pathway (focused on weight loss and reversal) should be given equal weight to the 'cardioprotective drug' pathway, especially for patients with a short duration of disease where the probability of successful remission is highest.

Clinical Landscape

Noteworthy Related Trials

1998

UKPDS 33

n = 3,867 · Lancet

Tested

Intensive blood glucose control (sulfonylurea or insulin)

Population

Newly diagnosed T2DM patients

Comparator

Conventional treatment (dietary advice)

Endpoint

Any diabetes-related endpoint

Key result: Intensive glucose control significantly reduced the risk of microvascular complications in patients with newly diagnosed type 2 diabetes.

2002

Diabetes Prevention Program (DPP)

n = 3,234 · NEJM

Tested

Intensive lifestyle intervention

Population

Adults with impaired glucose tolerance

Comparator

Metformin or placebo

Endpoint

Incidence of type 2 diabetes

Key result: Lifestyle intervention significantly reduced the incidence of type 2 diabetes compared to placebo and metformin.

2011

DIRECT Trial

n = 306 · Lancet

Tested

Weight management program (low-calorie diet)

Population

Patients with type 2 diabetes

Comparator

Standard best practice care

Endpoint

Diabetes remission (HbA1c <6.5%)

Key result: Substantial weight loss achieved through a low-calorie diet can induce remission of type 2 diabetes in the majority of patients.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis